We are live on ! Find out more
Balyasny Asset Management

Balyasny Asset Management Portfolio holdings

AUM $77.1B
1-Year Est. Return 42.89%
This Fund
S&P 500
This Quarter Est. Return
+7.45%
1 Year Est. Return
+42.89%
3 Year Est. Return
+126.29%
5 Year Est. Return
+172.74%
10 Year Est. Return
+1,026.86%
AUM
$32B
AUM Growth
+$6.48B
Cap. Flow
+$4.77B
Cap. Flow %
14.9%
Top 10 Hldgs %
10.84%
Holding
2,554
New
720
Increased
686
Reduced
602
Closed
529

Sector Composition

Rank Sector Weight
1 Financials 20.47%
2 Consumer Discretionary 12.5%
3 Healthcare 10.55%
4 Industrials 6.63%
5 Real Estate 6.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AQMS icon
1976
Aqua Metals
AQMS
$9.49M
$96K ﹤0.01%
+224
New +$169K
BNED icon
1977
Barnes & Noble Education
BNED
$439M
$95K ﹤0.01%
+115
New +$76K
AGEN
1978
Agenus
AGEN
$324M
$94K ﹤0.01%
1,465
-27,826
-95% -$2.12M
CDR
1979
DELISTED
Cedar Realty Trust, Inc
CDR
$93K ﹤0.01%
+2,323
New +$90.1K
LRFC
1980
DELISTED
Logan Ridge Finance Corp
LRFC
$92K ﹤0.01%
2,097
-1,467
-41% -$71.6K
PFX icon
1981
PhenixFIN
PFX
$89.2M
$90K ﹤0.01%
866
-84
-9% -$9.58K
OSG
1982
DELISTED
Overseas Shipholding Group Inc.
OSG
$88K ﹤0.01%
32,072
-4,151
-11% -$10.8K
CLDX icon
1983
Celldex Therapeutics
CLDX
$3.22B
$87K ﹤0.01%
2,040
-1,053
-34% -$45.1K
ATRS
1984
DELISTED
Antares Pharma, Inc.
ATRS
$87K ﹤0.01%
+43,950
New +$95.6K
WTI icon
1985
W&T Offshore
WTI
$484M
$85K ﹤0.01%
+25,752
New +$79.9K
ENZ
1986
DELISTED
Enzo Biochem, Inc.
ENZ
$85K ﹤0.01%
10,452
-10,200
-49% -$97.4K
MEET
1987
DELISTED
The Meet Group, Inc. Common Stock
MEET
$85K ﹤0.01%
30,248
-13,123
-30% -$39K
CMRX
1988
DELISTED
Chimerix, Inc.
CMRX
$81K ﹤0.01%
+17,429
New +$82.9K
MVIS icon
1989
Microvision
MVIS
$74M
$77K ﹤0.01%
+3,153
New +$91K
KG
1990
Kestrel Group
KG
$68.9M
$76K ﹤0.01%
579
-1,027
-64% -$154K
CETV
1991
DELISTED
Central European Media Enterprises Ltd
CETV
$76K ﹤0.01%
+16,400
New +$75.2K
CERS icon
1992
Cerus
CERS
$457M
$74K ﹤0.01%
21,800
-1,000
-4% -$3.39K
PSEC icon
1993
Prospect Capital
PSEC
$1.09B
$74K ﹤0.01%
11,015
-40,632
-79% -$265K
VOXX
1994
DELISTED
VOXX International Corporation Class A
VOXX
$74K ﹤0.01%
13,180
-5,100
-28% -$33.3K
TRVN
1995
DELISTED
Trevena, Inc.
TRVN
$74K ﹤0.01%
74
-656
-90% -$713K
TLGT
1996
DELISTED
Teligent, Inc
TLGT
$73K ﹤0.01%
+2,023
New +$96.8K
TXMD icon
1997
TherapeuticsMD
TXMD
$24M
$72K ﹤0.01%
+238
New +$66.3K
CMRE icon
1998
Costamare
CMRE
$1.77B
$67K ﹤0.01%
11,538
-15,062
-57% -$89.3K
LAB icon
1999
Standard BioTools
LAB
$307M
$65K ﹤0.01%
+11,100
New +$60.8K
IMUX icon
2000
Immunic
IMUX
$191M
$61K ﹤0.01%
+26
New +$57.5K

Similar funds

Balyasny Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Balyasny Asset Management held 2,554 positions worth $32B, up 25% from $25.5B the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Balyasny Asset Management deployed $4.77B of net new capital in Q4 2017, opening 720 new positions and adding to 686 existing holdings. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 1,700,000 shares worth $148M.

By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was American Express, an estimated $253M trimmed.

  • Balyasny Asset Management's largest Q4 2017 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 1,700,000 shares worth $148M.
  • Balyasny Asset Management added most to Aetna Inc in Q4 2017, an estimated $175M increase.
  • Balyasny Asset Management's biggest Q4 2017 reduction was American Express, cutting an estimated $253M.
  • Balyasny Asset Management fully exited Range Resources in Q4 2017, selling an estimated $104M.
  • Balyasny Asset Management's ten largest holdings make up 11% of its $32B portfolio in Q4 2017.
  • Balyasny Asset Management opened 720 new positions and closed 529 in Q4 2017.
  • Balyasny Asset Management's portfolio value rose 25% quarter-over-quarter to $32B.

Based on Balyasny Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.